key: cord-0784207-xhhsny1n
authors: Iglesias-Lopez, C.
title: Temporary derogation of European environmental legislation for clinical trials of genetically modified organisms (GMOs) for COVID-19
date: 2020-09-26
journal: Cytotherapy
DOI: 10.1016/j.jcyt.2020.09.005
sha: e92264d7a5359de28f90af2beb8657a9f0e5b833
doc_id: 784207
cord_uid: xhhsny1n

nan

Environmental legislation in the European Union 8

Biological therapies comprise a wide range of product types, including advanced therapies and vaccines. 9

Gene therapy medicinal products (GTMPs) are cutting-edge therapies and promise to treat indications 10 ranging from rare genetic diseases to cancers. GTMPs treat disease by replacing, inactivating, or introducing 11 a recombinant nucleic acid sequence into the body, typically using a viral vector or through other carrier 12 molecules. On the other hand, vaccines are a heterogeneous class of biological medicinal products aimed at 13 the treatment or prophylaxis of infectious diseases, and include not only classic vaccines consisting of 14 attenuated or inactivated microorganism, but also antigens produced through recombinant DNA technology, 15 chimeric microorganisms, live recombinant viral vectored vaccines, and others. When a biological entity is 16 capable of replication or of transferring altered genetic material, as is the case of many GTMPs or some 17 vaccines, it is also considered a genetically modified organism (GMO). 18

The clinical use of these therapies might pose a risk, since these products may enter the environment by 19

unintended dispersal or via excretion by the patient. This dissemination could potentially spread the GMO 20 further, and it could undergo genetic or phenotypic changes, infect, reproduce, remain latent, compete with 21 existing species or transfer its genetic material to other species, impacting human health and the 22 environment. In consequence, medicinal products consisting of or containing a GMO are regulated by the 23 environmental and human drugs legislation in the European Union (EU) and all its potential risks must be 24 evaluated by conducting an environmental risk assessment (ERA) during its development. To conduct a 25 clinical trial with a product based on a GMO, the Sponsor needs to obtain not only the authorisation from the 26 ethics committees and competent national health authorities (NHAs) where the study is going to take place, 27 but an additional one to "release" or to administer the GMO-containing medicinal product in that trial. To 28 obtain this authorisation, an ERA must be assessed and endorsed by the government authorities of each 29

Member State in charge of GMO evaluations and responsible for the environment in each country. 30

In recent years, especially with the increased development of advanced therapies, the lack of harmonisation 31 among the European countries and the burden that these environmental procedures entail for the Sponsor 32

have become notably evident. Although there is a common European framework in place, the environmental 33 EU Directives have been implemented differently across European countries. This fact has resulted in a 34 resource-intensive process, above all for multicentre studies, as sponsors of clinical trials need to submit 35 This is a provisional file, not the final typeset article multiple requests for environmental authorisations to multiple competent authorities in different Member 36

States, each with different requirements and ERA procedures that vary greatly from one Member State to 37

another. The result is the generation of huge delays in clinical development, an increase in logistical hurdles 38 at country level, and an higher costs (1). The European Commission recognised in 2018 the handicaps of 39 these procedures in the EU and initiated several dialogues with the NHAs with the aim to unify the 40 interpretation of the GMO framework. As a result, common position documents for genetically modified 41 human cells and for those products containing adeno-associated viruses were recently endorsed by most 42

NHAs. Nevertheless, this approach is still not enough, and this procedure remains substantially burdensome. 43 44 Temporary changes in the environmental legislation due to COVID-19 pandemic

COVID-19 has rapidly developed into a worldwide pandemic with a significant health impact and clinical trials 46 that aim to discover an effective vaccine are ongoing. Potential vaccines currently under development 47

include genetically modified viruses, which are classified as GMOs (2) (4)(5). Although these two Directives aim to ensure the protection of human health 53 and the environment through the assessment of the risks from the deliberate release or the contained use of 54

GMOs, it has been considered that the protection of public health -through the acceleration the 55 deployment of a COVID-19 vaccine -prevails in this unprecedented situation. Pivotal trials with promising 56 candidates will be conducted in several countries, and without this measure, European clinical trials could fall 57 behind those of United States (US) or China, delaying early access to these product candidates. The 58

derogation will apply as long as COVID-19 is regarded as a public emergency, but Sponsors should implement 59 appropriate measures to minimize the foreseeable negative environmental impact resulting from the release 60 of the investigational medicinal product into the environment. Compliance with good manufacturing 61

practices and an ERA of the products will still be mandatory before their marketing authorisation is granted. 62 63

This temporary derogation has been very controversial. On one hand, some expert groups have pointed out 64 that this measure could be irresponsible since the development of vaccines based on GMO viruses might 65 involve risks to human health and the environment, and these risks are not necessarily covered by the 66 general safety protocols aimed at protecting participants (6). In addition, supporters of the measure argue 67 that a clinical study with only small quantities of an investigational product and a limited number of patients, 68

should not have a significant cumulative effect into the environment. The same argument can be found in US 69 environmental regulation (7), whereby most investigational products are categorically excluded from the 70 requirement to submit an ERA, but this principle has not been applied in the EU so far and massive trials 71

including thousands of participants are expected for phase III studies with these vaccine candidates. being within the top ten causes of death in the EU and being the second leading cause of death globally (9). 81

These products, still have to deal with the intricacy of these environmental procedures and the delays that 82 this implies for the starting of the clinical studies in the EU, ultimately postponing the early access of these 83 products to patients. 84 85

Concluding remarks 86

Attempts to streamline environmental procedures among EU Member States have so far been unsuccessful. 87

With the temporary derogation from the environmental requirements for products intended to treat or 88 prevent COVID-19, the bottleneck and obstacles that the environmental legislation represents in the EU for 89 the development of innovative GMO-based medicines has become even more evident. Further efforts are 90 needed to centralise or rationalise this procedure with the main objective of enabling patients to benefit 91 from innovative medicines as soon as possible for a variety of diseases. 92 93

The author declare that the research was conducted in the absence of any commercial or financial 95 relationships that could be construed as a potential conflict of interest. 96

97 CIL reviewed the data and wrote the manuscript. 98

Hurdles of environmental risk assessment 100 procedures for advanced therapy medicinal products: comparison between the European Union and 101 the United States

Safety and 104 immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 105 1/2, single-blind

Communication from the Commission to the European Parliament the European Council the Council 111 and the European Investment Bank. EU Strategy for COVID-19 vaccines

Regulation (EU) 2020/1043 of the European Parliament and of 115 the Council of 15 July 2020 on the conduct of clinical trials with and supply of medicinal products for 116 human use containing or consisting of genetically modified organisms intended to treat or p 117

COGEM advice concerning the proposal by the EC to suspend the 120 environmental risk assessment of clinical trials for the treatment or prevention of

Advice-concerning-the-proposal-by-the-EC-to-suspend-the-environmental-risk-assessment-of-123 clinical-trials-for-the-treatment-or-prevention-of-COVID-19

Determining the Need for and Content of Environmental Assessments for Gene Therapies

Vectored Vaccines, and Related Recombinant Viral or Microbial Products: Guidance for Industry

Scheme for Temporary Regulations on Alternative Treatment Gene 129 Therapy Applications for Gene Therapy in Connection with Combating

World Health Organization. WHO | Top 10 causes of death